Recent Acquisition Growth Following its acquisition by Jabil for $20 billion, Pharmaceutics International has significantly expanded its global reach and manufacturing capabilities, presenting opportunities to offer integrated supply chain solutions and advanced manufacturing services to new and existing clients.

Innovative Development Platform The launch of the Accelevate Early Development Platform demonstrates Pii's commitment to accelerating drug development timelines, making it a prime partner for smaller pharmaceutical companies seeking to expedite IND submissions and streamline their development pipelines.

Industry Leadership & Trust Recognition as a trusted partner for top global brands underscores Pii's strong reputation in high-quality aseptic and oral dosage manufacturing, which can be leveraged to attract premium clients seeking reliable, high-standard pharma manufacturing solutions.

Expansion in High-Potential Tech Recent investments totaling $3.6 million in advanced labeling, fill/finish, and inspection technologies for prefilled syringes indicate a strategic focus on high-growth injectable markets, offering opportunities to provide specialized solutions for emerging biologics and specialty drugs.

Strong Industry Position With a revenue range of $500 million to $1 billion and established relationships with reputable companies, Pii is well-positioned to upsell and cross-sell complementary services such as advanced formulations, potent compound handling, and scalable manufacturing solutions to existing customers and prospects expanding their portfolio.